CA-CEPTON-TECHNOLOGIES
11.1.2021 12:02:50 CET | Business Wire | Press release
A ground-breaking lidar-based real-time crowd analytics solution has recently helped Orlando International Airport (MCO) create one of the world’s safest terminals during the COVID-19 pandemic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005374/en/
Deployed by The Indoor Lab, the leading provider for monitoring real-time foot traffic using lidar sensors, the solution - called Safe Place™ - uses Cepton’s award-winning Helius™ Smart Lidar System. Helius enables The Indoor Lab to provide intelligent, anonymized, 3D tracking of people, thereby dramatically improving the usability, safety and cleanliness of large spaces. Further, The Indoor Lab’s ground-breaking visual analytics platform, leveraging the Helius Smart Lidar System, powers the Synect Evenflow Crowd Radar media lights in terminal 2 of the Orlando International Airport.
The project at Orlando International Airport is one of several early projects initiated by The Indoor Lab and Cepton as part of a strategic partnership announced today. The Indoor Lab is Cepton’s early-stage development and analytics partner shaping the future of lidar analytics. This partnership lays the foundation for long-awaited innovations that will save customers time and money, enable more efficient design of public and private commercial spaces, and add a much-needed capability to improve public safety during the COVID-19 pandemic and recovery.
Patrick Blattner, co-founder and Chief Product Officer of The Indoor Lab said: “We have a 15-year history of crowd tracking across retail, events, airports, and stadiums. So, when COVID-19 started spreading exponentially and negatively affected many public and private spaces, we consulted with leaders involved in drafting proposals for the International Franchise Association, including the use of lidar technology to help put the country back on a path towards normalcy. With public concerns focused on cleanliness of public and commercial spaces, we extended our Safe Place platform beyond occupancy and social distancing, creating the first proprietary real-time sanitization detection solution in the market. A Safe Place enabled environment ensures locations have been cleaned, distancing measures are followed, and safer occupancy levels are maintained. Our partnership with Cepton helped us deliver against this promise. Our patent-pending Safe Place platform with real-time cleaning detection is the first of its kind in the world.”
According to The Indoor Lab, the full solution implemented in Orlando led to a drastic improvement in people’s adherence to social distancing through Thanksgiving and into the busy holiday travel season. The unprecedented effectiveness of The Indoor Lab’s innovative crowd analytics solution relies on the unique, high point density and detection range of Cepton’s MMT® -based Vista® -series lidars and Cepton’s award-winning Helius system that provides object dimensions, locations and velocities at high accuracy. The mirrorless, frictionless and rotation-free MMT architecture enables lidars that are reliable and easy to integrate for both indoor and outdoor applications. In addition, Helius allows easy aggregation of data from multiple Cepton lidar sensors to form a comprehensive and extendable network for seamless tracking. For instance, this allows the anonymized tracking of the same person across large overlapping areas, which, according to The Indoor Lab, is another game-changing factor that differentiates Helius from other lidar solutions.
In the Orlando International Airport deployment, the Indoor Lab used seven Vista lidar sensors from Cepton to seamlessly cover nearly 100% of the terminal area of roughly 50,000 square feet, something that would otherwise have required significantly more video cameras, each consuming far more data and storage bandwidth compared to the lidars. Unlike video cameras, lidars also perform accurately 24/7 regardless of lighting conditions.
Another key advantage of lidar, compared to cameras, is that it does not capture biometric data. While lidar sensors provide information to help detect, track and classify objects accurately, they do not show facial features and skin/hair color, maximizing protection of people’s privacy and reducing analytical bias. “The great thing about lidar-based crowd analytics is that it is compliant with privacy laws. At the same time, the system can also integrate with point, tilt, zoom (PTZ) cameras to detect potential public safety risks, such as a bag left behind in a public space or people unexpectedly moving at high rates of speed,” explained Blattner.
The partnership between Cepton and The Indoor Lab extends beyond projects in airports. Using Cepton’s technology, The Indoor Lab is successfully monitoring real-time traffic globally across hotels, stadiums, large commercial venues and retail spaces, such as malls and stores. The Indoor Lab’s software provides state-of-the-art, real-time information on crowd density, as well as dwell times, motion tracking and speed of individuals. Using all of that data, enterprises can optimize their customers’ experience in their spaces – to manage queues, reduce crowding, optimize layout of aisles, walkways and shops, as well as address safety and security risks.
“After evaluating most of the lidar hardware and 3D perception software offerings on the market, The Indoor Lab has identified Cepton to be the leader with a combined solution that provides the point-cloud density, accuracy, reliability, and ease and cost of integration required to properly enable crowd analytics. Together with the Cepton team, we have successfully monitored and analyzed dense crowds in some of the most challenging environments,” said Patrick Mooney, co-founder and CTO at The Indoor Lab.
Dr. Jun Pei, Cepton’s co-founder and CEO, said: “We are grateful for the partnership with The Indoor Lab and for their adoption of Cepton’s cutting-edge technology to deploy their pathbreaking innovations into a range of diverse applications. The power of this partnership is already evident in the remarkable results recently showcased by The Indoor Lab with their other partners.”
“We worked closely with The Indoor Lab to ensure we were able to deliver the capabilities and accuracy needed for their smart space applications at an affordable price. Our Helius team built a ground-breaking solution that combines intelligent, powerful lidar perception with ease of integration and data efficiency. In a future where smart spaces are pivotal to positively transforming people’s experience in travel, retail, hospitality, entertainment and beyond, I’m confident that Helius will continue to set the benchmark for world-class anonymized perception needed by world-leading partners such as The Indoor Lab.”
Cepton will be showcasing its state-of-the-art lidar solutions at CES 2021 from January 11 to January 14, 2021. Please visit Cepton’s virtual booth (requires CES registration) for more information about Helius and Cepton’s full suite of lidar offerings for various markets. During CES, Cepton’s CMO Dr. T. R. Ramachandran will present at an online webinar “Lidar, What’s the Future ” on Tuesday Jan 12 at 2 p.m. (PST), hosted by North American Lighting (NAL). Additionally, Dr. Ramachandran will discuss how lidar is transforming smart cities in a virtual panel discussion “Smart City Roundtable: What is a Smart City ?” on Jan 13 at 2 p.m. (PST), also hosted by NAL. Join the sessions online to learn more about the transformational nature of lidar technology and how Cepton’s smart lidar solutions are uniquely suited for large scale deployments in smart city and smart spaces applications.
About Cepton Technologies, Inc.
Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities , smart spaces and smart industrial applications. Cepton’s patented MMT® -based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, Japan and India, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn .
About The Indoor Lab
The Indoor Lab, is the leading provider for monitoring real-time foot traffic using lidar sensors. The Safe PlaceTM platform is the newest product within their portfolio of foot traffic analytic solutions and is shaping the safe return and re-opening for all businesses in the future. Beyond COVID-19, The Indoor Lab offers the most extensive combined experience in designing, developing, and deploying real-time location services for some of the most heavily trafficked retailers, monuments, airports, and stadiums worldwide. The founders were the first to introduce 3D lidar for public space tracking and have since become the market leaders delivering the most accurate privacy compliant tracking solutions in the world. For more information, visit www.theindoorlab.com and follow us on LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005374/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
